	US 12,076,418 B2
	Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
Jun Gao, Coquitlam (CA); Eric Hsu, Vancouver (CA); and Anthony Cheung, Vancouver (CA)
Assigned to ENGENE, INC., Montreal (CA)
Filed by ENGENE, INC., Montreal (CA)
Filed on Nov. 8, 2021, as Appl. No. 17/521,509.
Application 17/521,509 is a continuation of application No. 16/666,314, filed on Oct. 28, 2019, granted, now 11,167,045.
Application 16/666,314 is a continuation of application No. 16/101,327, filed on Aug. 10, 2018, granted, now 10,456,481, issued on Oct. 29, 2019.
Application 16/101,327 is a continuation of application No. 15/025,218, granted, now 10,046,066, issued on Aug. 14, 2018, previously published as PCT/CA2014/050921, filed on Sep. 25, 2014.
Prior Publication US 2022/0133907 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/36 (2006.01); A61K 9/51 (2006.01); A61K 48/00 (2006.01); C08B 37/08 (2006.01); C12N 15/88 (2006.01)

CPC A61K 48/005 (2013.01) [A61K 9/5161 (2013.01); C08B 37/003 (2013.01); C12N 15/88 (2013.01)]

25 Claims

1. A method for modulating an immune response in a patient in need thereof, the method comprising administering a therapeutically effective amount of a therapeutic nucleic acid encoding an immunomodulatory cytokine to a target tissue in the patient, wherein said administering comprises contacting said target tissue with a dually derivatized (DD) chitosan nucleic acid polyplex, said DD chitosan nucleic acid polyplex comprising a chitosan-derivative nanoparticle and said therapeutic nucleic acid, wherein the chitosan-derivative nanoparticle comprises chitosan functionalized with arginine (Arg) and an hydrophilic polyol (HP) of Formula VII:

wherein:

R²is selected from: H and hydroxyl;

R³is selected from H and hydroxyl; and

X is selected from: C₂-C₆alkylene optionally substituted with one or more hydroxyl substituents;

provided said hydrophilic polyol is not gluconic acid.